{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T21:58:05Z","timestamp":1762898285662},"reference-count":64,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2007,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>The licensed smallpox vaccine Dryvax is used as the standard in comparative immunogenicity and protection studies of new smallpox vaccine candidates. Although the correlates of protection against smallpox are unknown, recent studies have shown that a humoral response against the intracellular mature virion and extracellular enveloped virion (EV) forms of vaccinia virus is crucial for protection. Using a recombinant Semliki Forest virus (rSFV) vector system, we expressed a set of full-length EV proteins for the development of EV antigen-specific enzyme-linked immunosorbent assays (ELISAs) and the production of monospecific antisera. The EV-specific ELISAs were used to evaluate the EV humoral response elicited by Dryvax and the nonreplicating modified vaccinia virus Ankara (MVA) in mouse vaccination experiments comparing doses and routes of vaccination. Quantitatively similar titers of antibodies against EV antigens A33R, A56R, and B5R were measured in mice vaccinated with Dryvax and MVA when MVA was administered at a dose of 10<jats:sup>8<\/jats:sup>plaque-forming units. Further, a substantial increase in the EV-specific antibody response was induced in mice inoculated with MVA by using a prime-boost schedule. Finally, we investigated the abilities of the EV-expressing rSFV vectors to elicit the production of polyclonal monospecific antisera against the corresponding EV proteins in mice. The monospecific serum antibody levels against A33R, A56R, and B5R were measurably higher than the antibody levels induced by Dryvax. The resulting polyclonal antisera were used in Western blot analysis and immunofluorescence assays, indicating that rSFV particles are useful vectors for generating monospecific antisera.<\/jats:p>","DOI":"10.1128\/cvi.00050-07","type":"journal-article","created":{"date-parts":[[2007,6,28]],"date-time":"2007-06-28T04:42:49Z","timestamp":1183005769000},"page":"1032-1044","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":8,"title":["Characterization and Use of Mammalian-Expressed Vaccinia Virus Extracellular Membrane Proteins for Quantification of the Humoral Immune Response to Smallpox Vaccines"],"prefix":"10.1128","volume":"14","author":[{"given":"Alonzo D.","family":"Garci\u0301a","sequence":"first","affiliation":[{"name":"Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clement A.","family":"Meseda","sequence":"additional","affiliation":[{"name":"Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne E.","family":"Mayer","sequence":"additional","affiliation":[{"name":"Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arunima","family":"Kumar","sequence":"additional","affiliation":[{"name":"Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Merchlinsky","sequence":"additional","affiliation":[{"name":"Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry P.","family":"Weir","sequence":"additional","affiliation":[{"name":"Laboratory of DNA Viruses, Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.10.6260-6271.2005"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.0105-2896.2006.00392.x","volume":"211","year":"2006","unstructured":"Amanna, I. J., M. K. Slifka, and S. Crotty. 2006. Immunity and immunological memory following smallpox vaccination. Immunol. Rev.211:320-337.","journal-title":"Immunol. Rev."},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1099\/0022-1317-13-1-9","volume":"13","year":"1971","unstructured":"Appleyard, G., A. J. Hapel, and E. A. Boulter. 1971. An antigenic difference between intracellular and extracellular rabbitpox virus. J Gen. Virol.13:9-17.","journal-title":"J Gen. Virol."},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.virol.2004.05.004","volume":"325","year":"2004","unstructured":"Bell, E., M. Shamim, J. C. Whitbeck, G. Sfyroera, J. D. Lambris, and S. N. Isaacs. 2004. Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology325:425-431.","journal-title":"Virology"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0264-410X(98)00224-2","volume":"17","year":"1999","unstructured":"Berglund, P., M. N. Fleeton, C. Smerdou, and P. Liljestrom. 1999. Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice. Vaccine17:497-507.","journal-title":"Vaccine"},{"key":"e_1_3_2_7_2","first-page":"295","volume":"62","year":"1969","unstructured":"Boulter, E. A. 1969. Protection against poxviruses. Proc. R. Soc. Med.62:295-297.","journal-title":"Proc. R. Soc. Med."},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1073\/pnas.0510598103","volume":"103","year":"2006","unstructured":"Chen, Z., P. Earl, J. Americo, I. Damon, S. K. Smith, Y. H. Zhou, F. Yu, A. Sebrell, S. Emerson, G. Cohen, R. J. Eisenberg, J. Svitel, P. Schuck, W. Satterfield, B. Moss, and R. Purcell. 2006. Chimpanzee\/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus. Proc. Natl. Acad. Sci. USA103:1882-1887.","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.4049\/jimmunol.171.10.4969","volume":"171","year":"2003","unstructured":"Crotty, S., P. Felgner, H. Davies, J. Glidewell, L. Villarreal, and R. Ahmed. 2003. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J. Immunol.171:4969-4973.","journal-title":"J. Immunol."},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1073\/pnas.0408782102","volume":"102","year":"2005","unstructured":"Davies, D. H., X. Liang, J. E. Hernandez, A. Randall, S. Hirst, Y. Mu, K. M. Romero, T. T. Nguyen, M. Kalantari-Dehaghi, S. Crotty, P. Baldi, L. P. Villarreal, and P. L. Felgner. 2005. Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery. Proc. Natl. Acad. Sci. USA102:547-552.","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.18.11724-11733.2005"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","unstructured":"Earl P. N. Cooper L. Wyatt B. Moss and M. Carroll. 1998. Preparation of cell cultures and vaccinia virus stocks p. 16.16.1-16.16.13. In F. M. Ausubel et al. (ed.) Current protocols in molecular biology vol. 3. John Wiley and Sons Inc. New York NY.","DOI":"10.1002\/0471142727.mb1616s43"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","unstructured":"Earl P. L. N. Cooper L. Wyatt B. Moss and M. W. Carroll. 1998. Generation of recombinant vaccinia virus p. 16.17.1-16.17.19. In F. M. Ausubel et al. (ed.) Current protocols in molecular biology vol. 3. John Wiley and Sons Inc. New York NY.","DOI":"10.1002\/0471142727.mb1617s43"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nature02331","volume":"428","year":"2004","unstructured":"Earl, P. L., J. L. Americo, L. S. Wyatt, L. A. Eller, J. C. Whitbeck, G. H. Cohen, R. J. Eisenberg, C. J. Hartmann, D. L. Jackson, D. A. Kulesh, M. J. Martinez, D. M. Miller, E. M. Mucker, J. D. Shamblin, S. H. Zwiers, J. W. Huggins, P. B. Jahrling, and B. Moss. 2004. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature428:182-185.","journal-title":"Nature"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/0042-6822(92)90535-W","volume":"188","year":"1992","unstructured":"Engelstad, M., S. T. Howard, and G. L. Smith. 1992. A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope. Virology188:801-810.","journal-title":"Virology"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1067\/mai.2002.128052","volume":"110","year":"2002","unstructured":"Engler, R. J., J. Kenner, and D. Y. Leung. 2002. Smallpox vaccination: risk considerations for patients with atopic dermatitis. J. Allergy Clin. Immunol.110:357-365.","journal-title":"J. Allergy Clin. Immunol."},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1099\/0022-1317-81-3-749","volume":"81","year":"2000","unstructured":"Fleeton, M. N., P. Liljestrom, B. J. Sheahan, and G. J. Atkins. 2000. Recombinant Semliki Forest virus particles expressing louping ill virus antigens induce a better protective response than plasmid-based DNA vaccines or an inactivated whole particle vaccine. J. Gen. Virol.81:749-758.","journal-title":"J. Gen. Virol."},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1099\/0022-1317-80-5-1189","volume":"80","year":"1999","unstructured":"Fleeton, M. N., B. J. Sheahan, E. A. Gould, G. J. Atkins, and P. Liljestrom. 1999. Recombinant Semliki Forest virus particles encoding the prME or NS1 proteins of louping ill virus protect mice from lethal challenge. J. Gen. Virol.80:1189-1198.","journal-title":"J. Gen. Virol."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.19.10230-10237.2004"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1086\/375824","volume":"37","year":"2003","unstructured":"Fulginiti, V. A., A. Papier, J. M. Lane, J. M. Neff, and D. A. Henderson. 2003. Smallpox vaccination: a review, part I. Background, vaccination technique, normal vaccination and revaccination, and expected normal reactions. Clin. Infect. Dis.37:241-250.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1086\/375825","volume":"37","year":"2003","unstructured":"Fulginiti, V. A., A. Papier, J. M. Lane, J. M. Neff, and D. A. Henderson. 2003. Smallpox vaccination: a review, part II. Adverse events. Clin. Infect. Dis.37:251-271.","journal-title":"Adverse events. Clin. Infect. Dis."},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1006\/viro.1998.9516","volume":"254","year":"1999","unstructured":"Galmiche, M. C., J. Goenaga, R. Wittek, and L. Rindisbacher. 1999. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology254:71-80.","journal-title":"Virology"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/nm917","volume":"9","year":"2003","unstructured":"Hammarlund, E., M. W. Lewis, S. G. Hansen, L. I. Strelow, J. A. Nelson, G. J. Sexton, J. M. Hanifin, and M. K. Slifka. 2003. Duration of antiviral immunity after smallpox vaccination. Nat. Med.9:1131-1137.","journal-title":"Nat. Med."},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0042-6822(02)00038-7","volume":"306","year":"2003","unstructured":"Hooper, J. W., D. M. Custer, and E. Thompson. 2003. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology306:181-195.","journal-title":"Virology"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.9.4433-4443.2004"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.66.12.7217-7224.1992"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.virol.2005.08.008","volume":"343","year":"2005","unstructured":"Jones-Trower, A., A. Garcia, C. A. Meseda, Y. He, C. Weiss, A. Kumar, J. P. Weir, and M. Merchlinsky. 2005. Identification and preliminary characterization of vaccinia virus (Dryvax) antigens recognized by vaccinia immune globulin. Virology343:128-140.","journal-title":"Virology"},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1542\/peds.18.2.177","volume":"18","year":"1956","unstructured":"Kempe, C. H., T. O. Berge, and B. England. 1956. Hyperimmune vaccinal gamma globulin; source, evaluation, and use in prophylaxis and therapy. Pediatrics18:177-188.","journal-title":"Pediatrics"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1099\/0022-1317-83-10-2347","volume":"83","year":"2002","unstructured":"Krauss, O., R. Hollinshead, M. Hollinshead, and G. L. Smith. 2002. An investigation of incorporation of cellular antigens into vaccinia virus particles. J. Gen. Virol.83:2347-2359.","journal-title":"J. Gen. Virol."},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-138-6-200303180-00014","volume":"138","year":"2003","unstructured":"Lane, J. M., and J. Goldstein. 2003. Evaluation of 21st-century risks of smallpox vaccination and policy options. Ann. Intern. Med.138:488-493.","journal-title":"Ann. Intern. Med."},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1099\/0022-1317-83-1-209","volume":"83","year":"2002","unstructured":"Law, M., R. Hollinshead, and G. L. Smith. 2002. Antibody-sensitive and antibody-resistant cell-to-cell spread by vaccinia virus: role of the A33R protein in antibody-resistant spread. J. Gen. Virol.83:209-222.","journal-title":"J. Gen. Virol."},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1099\/vir.0.80660-0","volume":"86","year":"2005","unstructured":"Law, M., M. M. Putz, and G. L. Smith. 2005. An investigation of the therapeutic value of vaccinia-immune IgG in a mouse pneumonia model. J. Gen. Virol.86:991-1000.","journal-title":"J. Gen. Virol."},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1038\/nbt1291-1356","volume":"9","year":"1991","unstructured":"Liljestrom, P., and H. Garoff. 1991. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Bio\/Technology9:1356-1361.","journal-title":"Bio\/Technology"},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","unstructured":"Liljestr\u00f6m P. and H. Garoff. 1995. Expression of proteins using Semliki Forest virus vectors vol. 2. John Wiley & Sons Inc. New York NY.","DOI":"10.1002\/0471142727.mb1620s29"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.22.10535-10550.2000"},{"key":"e_1_3_2_36_2","first-page":"28","volume":"4","year":"2002","unstructured":"Lundstrom, K. 2002. Alphavirus-based vaccines. Curr. Opin. Mol. Ther.4:28-34.","journal-title":"Curr. Opin. Mol. Ther."},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.21.13454-13462.2005"},{"key":"e_1_3_2_38_2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.virol.2004.07.024","volume":"328","year":"2004","unstructured":"Lustig, S., C. Fogg, J. C. Whitbeck, and B. Moss. 2004. Synergistic neutralizing activities of antibodies to outer membrane proteins of the two infectious forms of vaccinia virus in the presence of complement. Virology328:30-35.","journal-title":"Virology"},{"key":"e_1_3_2_39_2","first-page":"225","volume":"41","year":"1978","unstructured":"Mayr, A., and K. Danner. 1978. Vaccination against pox diseases under immunosuppressive conditions. Dev. Biol. Stand.41:225-234.","journal-title":"Dev. Biol. Stand."},{"key":"e_1_3_2_40_2","first-page":"375","volume":"167","year":"1978","unstructured":"Mayr, A., H. Stickl, H. K. Muller, K. Danner, and H. Singer. 1978. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defense mechanism. Zentbl. Bakteriol. B167:375-390. (In German.)","journal-title":"Zentbl. Bakteriol. B"},{"key":"e_1_3_2_41_2","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1086\/421266","volume":"38","year":"2004","unstructured":"McCurdy, L. H., B. D. Larkin, J. E. Martin, and B. S. Graham. 2004. Modified vaccinia Ankara: potential as an alternative smallpox vaccine. Clin. Infect. Dis.38:1749-1753.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_42_2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.virol.2005.06.002","volume":"339","year":"2005","unstructured":"Meseda, C. A., A. D. Garcia, A. Kumar, A. E. Mayer, J. Manischewitz, L. R. King, H. Golding, M. Merchlinsky, and J. P. Weir. 2005. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model. Virology339:164-175.","journal-title":"Virology"},{"key":"e_1_3_2_43_2","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1099\/0022-1317-72-5-1031","volume":"72","year":"1991","unstructured":"Meyer, H., G. Sutter, and A. Mayr. 1991. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol.72:1031-1038.","journal-title":"J. Gen. Virol."},{"key":"e_1_3_2_44_2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.virol.2005.09.037","volume":"344","year":"2006","unstructured":"Moss, B. 2006. Poxvirus entry and membrane fusion. Virology344:48-54.","journal-title":"Virology"},{"key":"e_1_3_2_45_2","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.288.15.1901","volume":"288","year":"2002","unstructured":"Neff, J. M., J. M. Lane, V. A. Fulginiti, and D. A. Henderson. 2002. Contact vaccinia\u2014transmission of vaccinia from smallpox vaccination. JAMA288:1901-1905.","journal-title":"JAMA"},{"key":"e_1_3_2_46_2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0042-6822(92)90313-E","volume":"187","year":"1992","unstructured":"Payne, L. G. 1992. Characterization of vaccinia virus glycoproteins by monoclonal antibody precipitation. Virology187:251-260.","journal-title":"Virology"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.31.1.147-155.1979"},{"key":"e_1_3_2_48_2","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1099\/vir.0.81265-0","volume":"86","year":"2005","unstructured":"Putz, M. M., I. Alberini, C. M. Midgley, I. Manini, E. Montomoli, and G. L. Smith. 2005. Prevalence of antibodies to vaccinia virus after smallpox vaccination in Italy. J. Gen. Virol.86:2955-2960.","journal-title":"J. Gen. Virol."},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.70.6.3753-3762.1996"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.5.4192-4204.1998"},{"key":"e_1_3_2_51_2","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3201\/eid0706.010602","volume":"7","year":"2001","unstructured":"Rosenthal, S. R., M. Merchlinsky, C. Kleppinger, and K. L. Goldenthal. 2001. Developing new smallpox vaccines. Emerg. Infect. Dis.7:920-926.","journal-title":"Emerg. Infect. Dis."},{"key":"e_1_3_2_52_2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1476-9433-4-2","volume":"4","year":"2005","unstructured":"Slifka, M. K. 2005. The future of smallpox vaccination: is MVA the key? Med. Immunol.4:2.","journal-title":"Med. Immunol."},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.2.1092-1098.1999"},{"key":"e_1_3_2_54_2","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1099\/0022-1317-83-12-2915","volume":"83","year":"2002","unstructured":"Smith, G. L., A. Vanderplasschen, and M. Law. 2002. The formation and function of extracellular enveloped vaccinia virus. J. Gen. Virol.83:2915-2931.","journal-title":"J. Gen. Virol."},{"key":"e_1_3_2_55_2","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1055\/s-0028-1108143","volume":"99","year":"1974","unstructured":"Stickl, H., V. Hochstein-Mintzel, A. Mayr, H. C. Huber, H. Schafer, and A. Holzner. 1974. MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA). Dtsch. Med. Wochenschr.99:2386-2392. (In German.)","journal-title":"Dtsch. Med. Wochenschr."},{"key":"e_1_3_2_56_2","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1016\/S0264-410X(01)00075-5","volume":"19","year":"2001","unstructured":"Stittelaar, K. J., T. Kuiken, R. L. de Swart, G. van Amerongen, H. W. Vos, H. G. Niesters, P. van Schalkwijk, T. van der Kwast, L. S. Wyatt, B. Moss, and A. D. Osterhaus. 2001. Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine19:3700-3709.","journal-title":"Vaccine"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.12.7845-7851.2005"},{"key":"e_1_3_2_58_2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1099\/0022-1317-13-1-19","volume":"13","year":"1971","unstructured":"Turner, G. S., and E. J. Squires. 1971. Inactivated smallpox vaccine: immunogenicity of inactivated intracellular and extracellular vaccinia virus. J. Gen. Virol.13:19-25.","journal-title":"J. Gen. Virol."},{"key":"e_1_3_2_59_2","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1099\/0022-1317-78-8-2041","volume":"78","year":"1997","unstructured":"Vanderplasschen, A., M. Hollinshead, and G. L. Smith. 1997. Antibodies against vaccinia virus do not neutralize extracellular enveloped virus but prevent virus release from infected cells and comet formation. J. Gen. Virol.78:2041-2048.","journal-title":"J. Gen. Virol."},{"key":"e_1_3_2_60_2","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.micinf.2005.02.004","volume":"7","year":"2005","unstructured":"Viner, K. M., and S. N. Isaacs. 2005. Activity of vaccinia virus-neutralizing antibody in the sera of smallpox vaccinees. Microbes Infect.7:579-583.","journal-title":"Microbes Infect."},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.8.3771-3780.2000"},{"key":"e_1_3_2_62_2","doi-asserted-by":"crossref","first-page":"6773","DOI":"10.1073\/pnas.92.15.6773","volume":"92","year":"1995","unstructured":"Ward, G. A., C. K. Stover, B. Moss, and T. R. Fuerst. 1995. Stringent chemical and thermal regulation of recombinant gene expression by vaccinia virus vectors in mammalian cells. Proc. Natl. Acad. Sci. USA92:6773-6777.","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.6.4590-4599.1999"},{"key":"e_1_3_2_64_2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ijid.2005.12.001","volume":"10","year":"2006","unstructured":"Wittek, R. 2006. Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy. Int. J. Infect. Dis.10:193-201.","journal-title":"Int. J. Infect. Dis."},{"key":"e_1_3_2_65_2","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.vaccine.2006.10.009","volume":"25","year":"2007","unstructured":"Xiao, Y., L. Aldaz-Carroll, A. M. Ortiz, J. C. Whitbeck, E. Alexander, H. Lou, H. L. Davis, T. J. Braciale, R. J. Eisenberg, G. H. Cohen, and S. N. Isaacs. 2007. A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost. Vaccine25:1214-1224.","journal-title":"Vaccine"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00050-07","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00050-07","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T14:14:12Z","timestamp":1708006452000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00050-07"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":64,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["10.1128\/CVI.00050-07"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00050-07","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8]]},"assertion":[{"value":"2007-01-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2007-06-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}